By: Tomas Ronolski - AllPennyStocks.com News

Monday, August 31, 2026

An upfront cash infusion from a commercial asset sale sparked a massive morning rally in specialty pharma today, highlighting how non-dilutive liquidity events can rapidly re-rate microcap balance sheets. When a developer monetizes its majority stake in an approved drug to a global manufacturing partner, the market quickly rewards the immediate cash injection.

RedHill Biopharma Ltd. (Nasdaq: RDHL) advanced Monday after divesting its Talicia business to a subsidiary of Apotex Health Corp. (TSX: APTX) for $18M in cash upfront, plus up to additional $35M tied to worldwide net-sales milestones.

The deal transfers RedHill's 70% interest in Talicia to Apotex, which already owned the remaining 30% through its acquisition of Cumberland Pharmaceuticals' U.S. branded business. Talicia is an FDA-approved therapeutic for H. pylori infection, a primary cause of peptic ulcers and gastric cancer. Management stated the $18 million cash proceeds will immediately strengthen liquidity, scale its broader gastrointestinal (GI) commercial franchise, fund potential new FDA-approved product acquisitions, and accelerate an operational path to profitability. RedHill retains its core late-stage clinical programs, including opaganib, RHB-102, RHB-204, and RHB-107.

Next catalysts include capital deployment into new GI commercial assets, milestone disclosures under the Apotex agreement, and upcoming clinical trial updates across retained late-stage pipeline candidates.

Shares of RDHL have surged 66.4% on the Nasdaq, reaching US$1.10 on volume of about 90M shares.

Copyright © 2026 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.